The Role of Epigenetics in Disease andTreatment¶
Chapter 497 | Part 20: Emerging Topics in Clinical Medicine · Parts 19-20 – Consultative & Emerging Topics · Chapter 497
Key Clinical Points¶
- Epigenetics involves changes in phenotype independent of genotype, first coined by Conrad Waddington in 1942.
- Three primary mechanisms: DNA methylation, histone posttranslational modifications (hPTMs), and nucleosome remodeling.
- DNA methylation (5-mC) is associated with gene repression; DNMT1 maintains status during replication, while DNMT3A/3B perform de novo methylation.
- TET enzymes (TET1-3) facilitate the removal of 5-mC by oxidizing it to 5-hmC, 5-fC, and 5-caC.
- Histone acetylation (via KATs/HATs) loosens chromatin for transcription; HDACs remove acetyl groups to repress transcription.
- Specific histone marks: H3K4me3, H3K36me3, and H3K79me3 activate transcription; H3K27me3 and H3K9me3 repress it.
- Epigenetic drugs include DNMT inhibitors (azacitidine, decitabine) for MDS/AML, HDAC inhibitors for cutaneous T-cell lymphoma/multiple myeloma, and BET inhibitors for hematologic cancers.
- Cancer is a mixed genetic and epigenetic disease; 25-30% of cancer driver mutations occur in chromatin regulatory proteins.
- Heterochromatic regions have higher mutation frequencies due to reduced access for DNA repair machinery.
- Dietary factors explain 30% of variation in serum methionine, affecting SAM levels and histone methylation; high-fat diets reduce histone acetylation via ACLY/ACSS2 inhibition.
- DNA methylation at specific CpG sites is a more accurate predictor of chronological age than p16 expression or telomere length.
- MECP2 mutations cause Rett syndrome; MLL1 (KMT2A) translocations occur in ~80% of infant ALL and adult AML cases.
DEFINITION & OVERVIEW¶
• Definition: Changes in phenotype occurring throughout development independent of any changes to genotype. • Etymology: The prefix 'epi-' (Greek: over, outside of, around) describes mechanisms influencing gene expression and phenotypes without altering the underlying DNA sequence. • History: Term coined by Conrad Waddington in 1942. • Scope: An interdisciplinary field involving chemistry, genetics, development, differentiation, immunology, cancer, aging, and neuroscience.
Ethical Considerations & Placebo Effects¶
• Ethics: Never acceptable to deceive patients; however, managing expectations can improve outcomes. • Nocebo Effect: While it is not ethical to withhold information about side effects, clinicians should provide realistic expectations to foster adaptive mindsets. • Clinical Example (OIT): In a study of children with peanut allergies undergoing oral immunotherapy (OIT), those told that mild symptoms were signs of treatment success (rather than just side effects) showed less anxiety and improved IgG4 levels. • Placebo Concept: Viewed as a combination of psychological, social, and biological mechanisms integral to the overall treatment effect.
EPIDEMIOLOGY¶
• Cancer Prevalence: 25-30% of identified cancer driver mutations occur in chromatin regulatory proteins. • Chromatin Accessibility: Heterochromatic regions (compact) have higher mutation frequencies than euchromatic regions due to reduced access for DNA repair machinery. • Dietary Impact: Dietary factors explain 30% of variation in human serum methionine, affecting SAM levels and histone methylation; high-fat diets reduce histone acetylation via ACLY/ACSS2 inhibition. • Transgenerational Effects: Nutritional status of grandparents can influence grandchildren's phenotypes via epigenetic transmission. • Aging Dynamics: Age-dependent changes increase susceptibility to mutations and reduce transcriptional fidelity.
Cancer Epidemiology¶
• Mechanism: Loss of differentiation-promoting chromatin regulation combined with gain of stemness-promoting activities is a recurring theme in cancer. • EZH2 Role: Overexpressed in many advanced/metastatic solid tumors (breast, prostate, melanoma); represses p16 and other cell cycle genes via H3K27me3 deposition.
Aging Epidemiology¶
• Mechanism: Lifetime exposure disrupts chromatin; loss of histone proteins (H3, H4) occurs across taxa. → Experimental increase in H3/H4 can reverse age-related changes in mammalian cells and yeast (Saccharomyces cerevisiae). • Biomarkers: DNA methylation status at specific CpG sites is a more accurate predictor of chronological age than p16 expression or telomere length.
ETIOLOGY & PATHOPHYSIOLOGY¶
• Chromatin Structure: The nucleosome (147 bp DNA wrapped around an octamer of H2A, H2B, H3, and H4) is the fundamental unit. • Accessibility: Euchromatin (open) → transcriptionally active; Heterochromatin (compact) → transcriptionally repressed. • 3D Architecture: Folding and looping further contribute to epigenetic regulation.
DNA Methylation Mechanisms¶
• Primary Modification: Cytosine methylation of CpG dinucleotides (5-mC) associated with gene repression. • Enzymes: ◦ DNMT3A and 3B: Catalyze de novo methylation at CpG dinucleotides in transcribed and intergenic regions. ◦ DNMT1: Critical for maintenance of methylation state after DNA replication during S phase. • Removal Mechanism: TET enzymes (TET1-3) oxidize 5-mC to 5-hmC, then 5-fC, and finally 5-caC. → 5-fC and 5-caC are not recognized by DNMT1 and can be removed to return to unmethylated cytosine.
Histone Posttranslational Modifications (hPTMs)¶
• Diversity: Over 60 different covalent modifications on histone N- and C-terminal tails. • Function: Serve as signals for transcription, replication, DNA repair, and recombination. • Specific Marks: ◦ Phosphorylation: γH2A.X (Ser139) marks double-strand breaks; critical for repair recruitment. ◦ Ubiquitination: Mono-ubiquitination marks initiation/elongation; Polyubiquitination tags proteins for proteasomal degradation (dysfunction linked to neurodegeneration). ◦ SUMOylation: Involved in transcriptional repression. ◦ ADP-ribosylation: Mediated by PARPs; alters chromatin via recruitment of associated proteins. • Acetylation: ◦ Catalyzed by KATs/HATs; removes positive charge from lysine, loosening chromatin structure. ◦ H3K9ac and H3K27ac are typically associated with transcriptional activation. ◦ Removed by HDACs (including sirtuins). • Methylation: ◦ Mediated by KMTs; does not change electrostatic charge but creates binding sites for 'reader' proteins. ◦ Activation: H3K4me3, H3K36me3, and H3K79me3. ◦ Repression/Silencing: H3K27me3 and H3K9me3. ◦ Stability: More stable and slower turnover than acetylation.
Nucleosome Remodeling¶
• Mechanism: Use ATP hydrolysis to reposition/remove nucleosomes or exchange core histones. • Histone Variants: H2AZ (at initiation sites), H3.3 (over transcribed genes). • Complexes: ◦ SWI/SNF: Creates nucleosome-free regions for activation. ◦ ISWI: Evenly spaces nucleosomes to repress transcription. ◦ INO80: Exchanges H2A with H2AZ at start sites.
RNA Epigenetics¶
• Epitranscriptomics: Study of reversible methylation of RNAs (e.g., mRNA). • Mechanism: Leads to mRNA degradation or facilitates translation; occurs co-transcriptionally. • Enzymes: Writers (METTL3, METTL14); Demethylases (ALKBH5, FTO). • Metabolic Link: Dietary methionine/SAM levels affect H3K4me3. → High folate leads to increased methylation in rectal mucosa; low methyl donors reduce GI cancers in mice.
CLINICAL FEATURES¶
• Cancer: Epigenetic dysregulation contributes to chemotherapy resistance and failure of antitumor immunity. • Mechanism: Cancer is a mixed genetic and epigenetic disease; perturbations often affect chromatin-regulating enzymes.
Cancer Clinical Manifestations¶
• MECP2: Mutations cause Rett syndrome.
Neurologic and Psychiatric Disorders¶
• Mechanism: Aberrant regulation as a key modulator of genetic predisposition and environmental factors.
DIFFERENTIAL DIAGNOSIS¶
• Cancer vs. Aging: ◦ Cancer: Loss of differentiation-promoting regulation + gain of stemness. ◦ Aging: General increase in activating modifications + loss of repressive marks (H3K9me3, H3K27me3) → transcriptional noise.
Cancer Epigenetic Subtypes¶
• MLL1 (KMT2A): Translocations in ~80% of infant ALL and adult AML; prevents hematopoietic differentiation. • EZH2: Overexpressed in breast, prostate, melanoma; represses p16.
INVESTIGATIONS & DIAGNOSIS¶
- ChIP-seq: Uses formaldehyde crosslinking and NGS to map the genome-wide landscape of histone modifications and DNA-binding factors.
- ATAC-seq: Utilizes Tn5 transposase to identify DNA regulatory elements (promoters/enhancers) at single-cell level by mapping open chromatin.
- CUT&RUN: Uses micrococcal nuclease (MNase) to cleave DNA near target proteins; avoids formaldehyde and reduces required cell numbers.
- CUT&Tag: Replaces MNase with Tn5 transposase in the CUT&RUN protocol to profile histone modifications at single-cell level.
- Hi-C / Hi-ChIP: Uses 3C chromosome conformation capture to study 3D genome organization and Topologically Associated Domains (TADs).
MANAGEMENT & TREATMENT¶
- DNMT Inhibitors: ◦ Drugs: azacitidine, decitabine. ◦ Indications: MDS/AML.
- HDAC Inhibitors: ◦ Indications: Cutaneous T-cell lymphoma, multiple myeloma.
- BET Inhibitors: ◦ Indications: Hematologic cancers.
PROGNOSIS & COMPLICATIONS¶
• Cancer Prognosis: Epigenetic status (e.g., EZH2 levels, IDH mutations) influences differentiation and treatment response. • Aging Complications: Loss of H3K9me3/H3K27me3 leads to activation of transposable elements and transcriptional instability.
SPECIAL CONSIDERATIONS¶
• Metabolic-Epigenetic Interactions: ◦ 30% of serum methionine variation is linked to diet. ◦ Impact: Altered SAM levels → altered histone methylation → impact on differentiation and cancer risk. • Developmental Considerations: ◦ Epgrenetic modifications are critical for cell-type specificity during development.
KEY PEARLS & CLINICAL TRAPS¶
• Core Definition: Epigenetics = phenotype changes independent of genotype. • Key Enzymes: ◦ DNMT1 (maintenance), DNMT3A/3B (de novo). ◦ TET (demethylation via oxidation). ◦ KATs/HATs (acetylation), HDACs (deacetylation). • Critical Histone Marks: ◦ Activation: H3K4me3, H3K36me3, and H3K79me3. ◦ Repression: H3K27me3 and H3K9me3. • Clinical Markers: ◦ MLL1 (KMT2A) translocations in ~80% of infant ALL/adult AML. ◦ EZH2 overexpression in solid tumors. • Aging Marker: DNA methylation is a superior predictor of age than p16 or telomere length.